See every side of every news story
Get Started
SubscribeLogin
Donald Trump
Hamas
US Politics
Israel-Hamas Conflict
Elon Musk
US Economy
CPAC
Ukraine War
Volodymyr Zelenskyy
Basketball
Baseball
Vladimir Putin
Published • loading... • Updated

Pacific Biosciences of California (NASDAQ:PACB) Given Neutral Rating at Piper Sandler

Summary by marketbeat.com
Piper Sandler reaffirmed a "neutral" rating and set a $2.00 price target (down previously from $2.50) on shares of Pacific Biosciences of California in a report on Thursday.

1 Articles

All
Left
Center
1
Right
marketbeat.commarketbeat.com

Pacific Biosciences of California (NASDAQ:PACB) Given Neutral Rating at Piper Sandler

Piper Sandler reaffirmed a "neutral" rating and set a $2.00 price target (down previously from $2.50) on shares of Pacific Biosciences of California in a report on Thursday.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

marketbeat.com broke the news in on Friday, February 21, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Menlo Park

Menlo Park

News
For You
Search
BlindspotLocal